# Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer

> **NCT05305131** · PHASE2 · RECRUITING · sponsor: **National University Hospital, Singapore** · enrollment: 50 (estimated)

## Conditions studied

- Nasopharyngeal Cancer

## Interventions

- **DRUG:** cisplatin and gemcitabine
- **DRUG:** induction chemotherapy cisplatin, gemcitabine, bevacizumab and pembrolizumab.

## Key facts

- **NCT ID:** NCT05305131
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-28
- **Primary completion:** 2025-12-28
- **Final completion:** 2026-12-28
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05305131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05305131, "Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05305131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*